The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Immunosuppressive Medicines Do Not Worsen COVID-19 Outcomes

Immunosuppressive Medicines Do Not Worsen COVID-19 Outcomes

February 17, 2021 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—Medications that suppress the immune system—necessary for many chronic diseases—do not worsen outcomes of COVID-19 cases, new data suggest.

You Might Also Like
  • Infection Rates for Patients with SLE on Immunosuppressive Drugs
  • Oxford University to Study Adalimumab as Potential COVID-19 Treatment
  • Biologic Treatment Recommendations for Rheumatic Disease Patients Who Contract COVID-19

Researchers looked back at 2,121 adults hospitalized for COVID-19 between March and August, including 108 who were taking immunosuppressive drugs (primarily prednisone, tacrolimus or mycophenolate mofetil).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

After accounting for patients’ general baseline health status, researchers found no significant differences between those who did or did not take immunosuppressive drugs in the risk of needing mechanical ventilation, the risk of dying, or the amount of time they were hospitalized.

“Our results contribute to a growing body of evidence that should provide reassurance to clinicians and patients using chronic immunosuppressive medicines,” the researchers wrote in Clinical Infectious Diseases.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. Andersen KM, Mehta HB, Palamuttam N, et al. Association between chronic use of immunosuppresive drugs and clinical outcomes from coronavirus disease 2019 (COVID-19) hospitalization: A retrospective cohort study in a large U.S. health system. Clin Infect Dis. 2021 Jan 7;ciaa1488. Online ahead of print.

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: COVID-19, hospitalized, immunosuppressive drugs

You Might Also Like:
  • Infection Rates for Patients with SLE on Immunosuppressive Drugs
  • Oxford University to Study Adalimumab as Potential COVID-19 Treatment
  • Biologic Treatment Recommendations for Rheumatic Disease Patients Who Contract COVID-19
  • Hydroxychloroquine for COVID-19 Fails Another Test

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.